Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide

sorafenib has been researched along with 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide in 1 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide)		Trials
(4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide)		Recent Studies (post-2010) (4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide)
6,5207305,25116316

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide (IC50)
NUAK family SNF1-like kinase 1Homo sapiens (human)0.004
Tyrosine-protein kinase JAK2Homo sapiens (human)0.006
Tyrosine-protein kinase JAK1Homo sapiens (human)0.012
Tyrosine-protein kinase JAK3Homo sapiens (human)0.008

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bharate, SB; Raghuvanshi, R1

Other Studies

1 other study(ies) available for sorafenib and 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide

ArticleYear
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022